OTCMKTS:ELTP Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis $0.62 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest About Elite Pharmaceuticals Stock (OTCMKTS:ELTP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Elite Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.61▼$0.6350-Day Range$0.37▼$0.7152-Week Range$0.12▼$0.75Volume1.66 million shsAverage Volume2.79 million shsMarket Capitalization$658.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewElite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.Read More… The #1 ETF for monthly income (Ad)We just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.Click here to get the full story >> Elite Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks14th Percentile Overall ScoreELTP MarketRank™: Elite Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Elite Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elite Pharmaceuticals is -61.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elite Pharmaceuticals is -61.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElite Pharmaceuticals has a P/B Ratio of 15.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.15% of the outstanding shares of Elite Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverElite Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elite Pharmaceuticals has recently decreased by 22.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElite Pharmaceuticals does not currently pay a dividend.Dividend GrowthElite Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.15% of the outstanding shares of Elite Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverElite Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elite Pharmaceuticals has recently decreased by 22.13%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.27 News SentimentElite Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Elite Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 7 people have searched for ELTP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Elite Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.01% of the stock of Elite Pharmaceuticals is held by institutions.Read more about Elite Pharmaceuticals' insider trading history. Receive ELTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ELTP Stock News HeadlinesElite Pharmaceuticals (OTCMKTS:ELTP) Receives FDA Approval for Generic Vyvanse®November 20, 2024 | americanbankingnews.comElite Pharmaceuticals Gains FDA Approval for Generic VyvanseNovember 19, 2024 | markets.businessinsider.comI've got news for you… Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekNovember 24, 2024 | DTI (Ad)Elite Pharmaceuticals, Inc. (PNK:ELTP) Q2 2025 Earnings Call TranscriptNovember 18, 2024 | msn.comElite Pharmaceuticals, Inc. (ELTP) Q2 2025 Earnings Conference Call TranscriptNovember 16, 2024 | seekingalpha.comElite Pharmaceuticals Reports Strong Q2 2025 Financial ResultsNovember 16, 2024 | markets.businessinsider.comElite Pharmaceuticals Inc (ELTP) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...October 9, 2024 | finance.yahoo.comElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate SodiumAugust 27, 2024 | finanznachrichten.deSee More Headlines ELTP Stock Analysis - Frequently Asked Questions How have ELTP shares performed this year? Elite Pharmaceuticals' stock was trading at $0.14 at the beginning of the year. Since then, ELTP shares have increased by 340.6% and is now trading at $0.6168. View the best growth stocks for 2024 here. How were Elite Pharmaceuticals' earnings last quarter? Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) issued its earnings results on Thursday, June, 14th. The specialty pharmaceutical company reported $0.00 earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $1.60 million during the quarter. Elite Pharmaceuticals had a positive trailing twelve-month return on equity of 15.55% and a negative net margin of 8.98%. How do I buy shares of Elite Pharmaceuticals? Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Elite Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), iBio (IBIO) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings6/14/2018Today11/24/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ELTP CUSIPN/A CIK1053369 Webwww.elitepharma.com Phone(201) 750-2646Fax201-750-2755Employees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$20.11 million Net Margins-8.98% Pretax Margin-9.52% Return on Equity15.55% Return on Assets9.74% Debt Debt-to-Equity Ratio0.10 Current Ratio3.52 Quick Ratio2.42 Sales & Book Value Annual Sales$56.62 million Price / Sales11.64 Cash Flow$0.03 per share Price / Cash Flow21.06 Book Value$0.04 per share Price / Book15.42Miscellaneous Outstanding Shares1,068,270,000Free Float914,228,000Market Cap$658.91 million OptionableNot Optionable Beta0.18 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:ELTP) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elite Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elite Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.